Abstract
Background: Radiotherapy for pituitary adenomas is an effective treatment but remains controversial due to toxicity concerns. Materials and methods: A retrospective audit of patients referred for radiotherapy during 1974-2003 was conducted, the case records were examined and data linkage to cancer registry and hospital discharge records was performed to assess the overall survival (OS), progression-free survival (PFS) and late effects (hormone deficiency, reduced vision, second cancer and stroke). Results: Three hundred and eighty-five patients had radiotherapy (median 45 Gy). The OS was 74% and 49%, PFS was 97% and 96%, at 10 and 20 years, respectively. No specific factors influenced local control. Additional hormone deficiencies occurred in 19% (ACTH) and 26% (TSH). Actuarial rate optic neuropathy at 10 years was 0.8%. Seventy-eight patients had a stroke, a RR for a matched Scottish population of 1.45 (CI 1.05-1.18, p = 0.03) men and 2.22 (1.56-3.08, p < 0.01) women. Four intra-cranial tumours were identified; 20-year actuarial risk 1.9% (CI 0-2.6%), a RR of 5.65 (0.53-20.77, p = 0.10) men and 9.94 (0.94-36.56, p = 0.04) women. Conclusions: This treatment is effective with good local control rates at 20 years. A significant proportion developed hypo-pituitarism. The risk of optic neuropathy was low
More>>
Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom);
Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)];
Conkey, David S;
[1]
Stockton, Diane;
[2]
Strachan, Mark W.J.;
[3]
Statham, Patrick F.X.;
Whittle, Ian R;
Grant, Robin;
[4]
Kerr, Gillian R;
[5]
Gregor, Anna;
[4]
Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)]
- Belfast City Hospital, Northern Ireland Cancer Centre (United Kingdom)
- ISD, NHS National Services Scotland, Edinburgh (United Kingdom)
- Metabolic Unit, University of Edinburgh (United Kingdom)
- Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom)
- Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)
Citation Formats
Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom), Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)], Conkey, David S, Stockton, Diane, Strachan, Mark W.J., Statham, Patrick F.X., Whittle, Ian R, Grant, Robin, Kerr, Gillian R, Gregor, Anna, and Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)].
Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity.
Ireland: N. p.,
2009.
Web.
doi:10.1016/j.radonc.2009.09.011.
Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom), Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)], Conkey, David S, Stockton, Diane, Strachan, Mark W.J., Statham, Patrick F.X., Whittle, Ian R, Grant, Robin, Kerr, Gillian R, Gregor, Anna, & Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)].
Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity.
Ireland.
https://doi.org/10.1016/j.radonc.2009.09.011
Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom), Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)], Conkey, David S, Stockton, Diane, Strachan, Mark W.J., Statham, Patrick F.X., Whittle, Ian R, Grant, Robin, Kerr, Gillian R, Gregor, Anna, and Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)].
2009.
"Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity."
Ireland.
https://doi.org/10.1016/j.radonc.2009.09.011.
@misc{etde_21343479,
title = {Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity}
author = {Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom), Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)], Conkey, David S, Stockton, Diane, Strachan, Mark W.J., Statham, Patrick F.X., Whittle, Ian R, Grant, Robin, Kerr, Gillian R, Gregor, Anna, and Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)]}
abstractNote = {Background: Radiotherapy for pituitary adenomas is an effective treatment but remains controversial due to toxicity concerns. Materials and methods: A retrospective audit of patients referred for radiotherapy during 1974-2003 was conducted, the case records were examined and data linkage to cancer registry and hospital discharge records was performed to assess the overall survival (OS), progression-free survival (PFS) and late effects (hormone deficiency, reduced vision, second cancer and stroke). Results: Three hundred and eighty-five patients had radiotherapy (median 45 Gy). The OS was 74% and 49%, PFS was 97% and 96%, at 10 and 20 years, respectively. No specific factors influenced local control. Additional hormone deficiencies occurred in 19% (ACTH) and 26% (TSH). Actuarial rate optic neuropathy at 10 years was 0.8%. Seventy-eight patients had a stroke, a RR for a matched Scottish population of 1.45 (CI 1.05-1.18, p = 0.03) men and 2.22 (1.56-3.08, p < 0.01) women. Four intra-cranial tumours were identified; 20-year actuarial risk 1.9% (CI 0-2.6%), a RR of 5.65 (0.53-20.77, p = 0.10) men and 9.94 (0.94-36.56, p = 0.04) women. Conclusions: This treatment is effective with good local control rates at 20 years. A significant proportion developed hypo-pituitarism. The risk of optic neuropathy was low but risk of stroke increased, particularly in women who had slight increased risk of intra-cranial tumours.}
doi = {10.1016/j.radonc.2009.09.011}
journal = []
issue = {3}
volume = {93}
place = {Ireland}
year = {2009}
month = {Dec}
}
title = {Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity}
author = {Erridge, Sara C., E-mail: serridge@staffmail.ed.ac.u [Edinburgh Centre for Neuro-Oncology, University of Edinburgh (United Kingdom), Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)], Conkey, David S, Stockton, Diane, Strachan, Mark W.J., Statham, Patrick F.X., Whittle, Ian R, Grant, Robin, Kerr, Gillian R, Gregor, Anna, and Edinburgh Cancer Centre, Western General Hospital, Edinburgh (United Kingdom)]}
abstractNote = {Background: Radiotherapy for pituitary adenomas is an effective treatment but remains controversial due to toxicity concerns. Materials and methods: A retrospective audit of patients referred for radiotherapy during 1974-2003 was conducted, the case records were examined and data linkage to cancer registry and hospital discharge records was performed to assess the overall survival (OS), progression-free survival (PFS) and late effects (hormone deficiency, reduced vision, second cancer and stroke). Results: Three hundred and eighty-five patients had radiotherapy (median 45 Gy). The OS was 74% and 49%, PFS was 97% and 96%, at 10 and 20 years, respectively. No specific factors influenced local control. Additional hormone deficiencies occurred in 19% (ACTH) and 26% (TSH). Actuarial rate optic neuropathy at 10 years was 0.8%. Seventy-eight patients had a stroke, a RR for a matched Scottish population of 1.45 (CI 1.05-1.18, p = 0.03) men and 2.22 (1.56-3.08, p < 0.01) women. Four intra-cranial tumours were identified; 20-year actuarial risk 1.9% (CI 0-2.6%), a RR of 5.65 (0.53-20.77, p = 0.10) men and 9.94 (0.94-36.56, p = 0.04) women. Conclusions: This treatment is effective with good local control rates at 20 years. A significant proportion developed hypo-pituitarism. The risk of optic neuropathy was low but risk of stroke increased, particularly in women who had slight increased risk of intra-cranial tumours.}
doi = {10.1016/j.radonc.2009.09.011}
journal = []
issue = {3}
volume = {93}
place = {Ireland}
year = {2009}
month = {Dec}
}